Page 2 - Scientific Library

Hyaluronic acid (HA), or hyaluronan, is an ubiquitous, very high molecular mass polysaccharide that has applications in a variety

Hyaluronic Acid (HA) is important in many biological processes such as wound repair, tissue hydration and inflammation. HA is also a potential biomarker for diseases such as osteoarthritis, liver cirrhosis

CRISPR/Cas9 is relatively simple to implement, as the researcher fully controls the experimental design of the tools, from the sgRNA sequence to the Cas9 protein.

In March 2016, Mark J Osborn et al published in Molecular Therapy a major article for genome editing (doi:10.1038/mt.2015.197), about knock-out of CD3 in human T-cells. The goal is to improve T-cell-based

Autotaxin (ATX) is a secreted lysophospholipase D involved in the release of the lipid mediator LPA. Many research tools have been developed to study ATX-LPA signaling.  In this post, I invite you

Messenger RNAs - a promising class of new therapeutic biologics

As messenger RNAs (mRNAs) are easier to deliver into cells than plasmids or viral vectors, they are useful for non-dividing cells. Inversely

Sequence engineering and chemical modification of CAS9 mRNA

For transgenesis and

Vector-free CRISPR-CAS9 gene editing to accelerate therapeutic applications

A few years ago, Ayal Hendel et al (doi:10.1038/nbt.3290) published results revealing that chemical alterations to sgRNA enhance

This summer, Moffett et al. published in Nature Communications (Nature Communications - doi:10.1038/s41467-017-00505-8) a new approach for cancer therapeutic research and development based on mRNA

RNA-based CRISPR-CAS9 gene editing is a vector-free approach that is required for therapeutic perspectives. However, from a practical point of view, what appears as a major challenge to engineer primary

Messenger RNA can be used for protein expression into the cells. The delivery of mRNA is the delivery of a new function that can activate a biological process. In the particular case of the CAS9 mRNA,

In a previous post, I introduced Sekisui Xenotech's Research Biobank, which is based on rejections from liver transplantation as opposed to post-mortem tissues, thus offering a guarantee for better tissue